16:33 EDT NanoViricides (NNVC) files $50M mixed securities shelfClaim 55% Off TipRanksUnlock trusted, data-backed investing tools with TipRanks ...
Discover high-conviction stock picks and new investing opportunities with the TipRanks Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on NNVC:Disclaimer & DisclosureReport an Issue
NanoViricides says NV-387 ready to be shipped to DRC for ebola
Partillion Bioscience Showcases Nanovials as a Leading Platform for Cellular Interaction Analysis at CYTO 2026
2026 Letter to Nano One Stakeholders
Nano One Provides Summary of the Results from 2026 Annual General Meeting
Race for Ebola vaccine gets $60m boost - Businessday NG
Onco-Innovations Signs LOI with Nanosoft Polymers to Advance Polymer and Drug Delivery Development for the ONC010 Program
Advanced NanoTherapies Secures Over $31M Series B to Deliver First-of-its-Kind Dual-Drug (Paclitaxel and Sirolimus) Nanoparticle-Coated Balloon Platform for Vascular Treatment
NuRAN Wireless Secures USD 12 Million Debt Financing Mandate Letter, Launches in Ivory Coast and Accelerates African Expansion
Merck weighs use of COVID antiviral Lagevrio as Ebola outbreak worsens: report
Race for Ebola vaccine gets $50m boost as medics struggle to trace contacts | The National
Three New Ebola Vaccines Are in The Works. Here's The Science Behind Them.
SHELTON, CT / ACCESS Newswire / May 18, 2026 / NanoViricides, Inc. (NYSE American:NNVC) ("NanoViricides" or the "Company"), a…
16:18 EDT Unicycive Therapeutics (UNCY) files $150M mixed securities shelfClaim 55% Off TipRanksUnlock trusted, data-backed…
The company now has tangible progress on multiple nuclear business segments.
Partillion Bioscience Showcases Nanovials as a Leading Platform for Cellular Interaction Analysis at CYTO 2026
Nano One® Materials Corp. ("Nano One" or the "Company") (TSX:NANO)(OTCQB:NNOMF)(Frankfurt:LBMB), a process technology company…
LifeSci Capital analyst Patrick Dolezal maintained a Buy rating on Neurogene today and set a price target of $60.00.Claim 55% Off…
